Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclooxygenase and lipoxygenase pathway enzymes are two major families of iron-containing oxidative enzymes involved in the metabolism of arachidonic acid and related polyunsaturated fatty acids into bioactive lipid mediators known as eicosanoids[4][5][1]. Cyclooxygenases (COX; prostaglandin-endoperoxide synthase, PTGS) catalyze the conversion of arachidonic acid to prostaglandin H2 (PGH2), a precursor to prostanoids such as prostaglandins, prostacyclin, and thromboxanes, which play central roles in inflammation, pain, fever, platelet aggregation, and other physiological processes[5][2][3][6]. Two main COX isoforms exist in humans: COX-1 (constitutively expressed, physiologic homeostasis) and COX-2 (inducible, inflammation and disease contexts)[2][5][6]. Lipoxygenases (LOX) comprise a family of enzymes that oxygenate polyunsaturated fatty acids such as arachidonic acid, resulting in hydroperoxy derivatives that are further converted to leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids (HETEs), key mediators in inflammation, allergy, asthma, and immune regulation[1][2][4]. Several LOX isoforms exist, defined by their regioselectivity (e.g., 5-LOX, 12-LOX, 15-LOX), each producing distinct sets of lipid mediators[4][1]. Both COX and LOX pathways are well-established therapeutic targets. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit COX activity to manage pain and inflammation, while leukotriene pathway modulators (e.g., zileuton, montelukast) target LOX products for asthma and allergy treatment[5][2]. Key safety challenges include gastrointestinal toxicity, cardiovascular risk (COX inhibitors), and hepatotoxicity (LOX inhibitors)[5].
Inhibition of prostaglandin synthesis (NSAIDs, COX inhibitors), Inhibition of leukotriene synthesis (LOX inhibitors), Selective COX-2 inhibition
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclooxygenase and lipoxygenase pathway enzyme (COX and LOX).